Department of Otorhinolaryngology-Head and Neck Surgery, Korea University Ansan Hospital, Ansan, Gyeonggi-do, Republic of Korea.
Department of Otorhinolaryngology-Head and Neck Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of Korea.
Laryngoscope. 2021 Jun;131(6):E1903-E1909. doi: 10.1002/lary.29225. Epub 2020 Oct 28.
When conservative therapy fails for chronic parotitis, sialendoscopic treatment or surgical excision can be considered. However, these are financially costly or invasive. Thus, this study aimed to evaluate the clinical efficacy and safety of botulinum toxin (BTX) injection and to further analyze its effect on parotid gland function and volume using salivary single-photon emission computed tomography (SPECT)-computed tomography (CT).
This clinical trial has been registered in the Clinical Research Information Service, Republic of Korea. Fourteen patients with chronic parotitis received BTX injections into the parotid glands. Pain, postprandial pain, swelling, aesthetic discomfort, and salivary flow rate were assessed before injection, at 2 weeks, and at 1, 3, and 6 months. Salivary SPECT-CT was performed before injection and again 3 and 6 months after to assess the volume and uptake changes.
All subjective symptoms decreased significantly until 1 month and then increased. However, at 6 months, all subjective symptoms were determined to be better than before injection. The unstimulated and stimulated salivary flow rate did not show a significant difference over time. No significant difference was noted in parotid gland volume or uptake on salivary SPECT-CT over time.
BTX injection can be an alternative treatment option for chronic parotitis.
4 Laryngoscope, 131:E1903-E1909, 2021.
对于慢性涎腺炎，如果保守治疗失败，可以考虑采用涎内镜治疗或手术切除。然而，这些方法费用高或具有侵袭性。因此，本研究旨在评估肉毒毒素（BTX）注射的临床疗效和安全性，并进一步分析其对腮腺功能和体积的影响，使用唾液单光子发射计算机断层扫描（SPECT）-计算机断层扫描（CT）。
本临床试验已在韩国临床研究信息服务处注册。14 例慢性涎腺炎患者接受 BTX 腮腺内注射。在注射前、注射后 2 周、1 个月、3 个月和 6 个月评估疼痛、餐后疼痛、肿胀、美学不适和唾液流率。在注射前和 3 个月及 6 个月后再次进行唾液 SPECT-CT，以评估体积和摄取变化。
所有主观症状在 1 个月内显著减轻，然后增加。然而，在 6 个月时，所有主观症状均被认为比注射前更好。未刺激和刺激唾液流率随时间无显著差异。唾液 SPECT-CT 显示腮腺体积或摄取随时间无显著差异。
BTX 注射可作为慢性涎腺炎的一种替代治疗选择。
4 级喉镜，131：E1903-E1909，2021 年。
